Indeed, inactivation of USP2 increases the levels of both p53 and PD-L1 in tumors, suggesting that the tumor suppression activity of USP2 inhibition may be potentiated by the PD-1/PD-L1 immune checkpoint blockade. Here, USP2 is linked to neoplasm.